الإحصائيات الأساسية
| LEI | Y68YJHVB1GU4TAU3C223 |
| CIK | 1124804 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Veradigm Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 20, 2025 |
8-A12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 4) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer |
|
| August 20, 2025 |
Veradigm Amends and Extends Stockholder Rights Plan EX-99.1 Exhibit 99.1 Veradigm Amends and Extends Stockholder Rights Plan Chicago – August 20, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the “Board”) has approved an amendment to extend the Company’s existing Stockholder Rights Plan for an additional six months (the “Rights Plan”). The Rights Plan, |
|
| August 20, 2025 |
AMENDMENT NO. 5 TO STOCKHOLDER RIGHTS AGREEMENT EX-4.6 Exhibit 4.6 AMENDMENT NO. 5 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 5 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of August 20, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 18, 2025 |
VERADIGM inc. EMPLOYMENT AGREEMENT Exh. 10.1 VERADIGM inc. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made this 15th day of August, 2025 (the “Signing Date”) and effective as of September 2, 2025 (the “Effective Date”), by and between Veradigm Inc., a corporation organized and existing under the laws of the State of Delaware (“Company”), and Donald Trigg (“Executive”). RECITALS WHEREAS, commencing on the E |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 18, 2025 |
Exh. 99.1 Veradigm Appoints Don Trigg as Chief Executive Officer Former apree health CEO, Cerner President will Lead Next Phase of Company Growth CHICAGO – August 18, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that its Board of Directors has appointed Don Trigg, an industry leader with over two decades of healthcare technology |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T |
|
| July 24, 2025 |
AMENDMENT STOCKHOLDER AGREEMENT EX-10.1 Exhibit 10.1 AMENDMENT TO STOCKHOLDER AGREEMENT This AMENDMENT (this “Amendment”), dated as of July 24, 2025, is by and among Veradigm Inc. (the “Company”), Charles Myers (“Myers”) and Jessica Myers (together with Myers, the “Myers Parties”). Each of the Company, on the one hand, and Myers or the Myers Parties, on the other hand, is referred to herein as a “party”, and all of the Company a |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 24, 2025 |
EX-3.1 Exhibit 3.1 THIRD AMENDMENT TO BY-LAWS OF VERADIGM INC. (A DELAWARE CORPORATION), AS AMENDED AND RESTATED ON AUGUST 18, 2015 This Third Amendment (this “Amendment”) to the By-Laws, as amended and restated on August 18, 2015 and as further amended on January 1, 2023 and December 7, 2023 (the “By-Laws”), of Veradigm Inc., a Delaware corporation f/k/a Allscripts Healthcare Solutions, Inc. (the |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 23, 2025 |
Veradigm Provides 2025 Financial & Business Update Exhibit 99.1 Veradigm Provides 2025 Financial & Business Update CHICAGO – June 23, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, is providing an update on commercial activity and estimated financial performance for the first quarter of 2025 compared to the prior year, details about its recent financing, and reaffirmation of its outlook for the 20 |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 20, 2025 |
EX-10.1 Exhibit 10.1 Execution Version CREDIT AGREEMENT among VERADIGM INC., and VERADIGM LLC, as Borrowers, the Lenders Party Hereto, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Administrative Agent and Collateral Agent Dated as of June 18, 2025 THE LOANS ISSUED PURSUANT TO THIS AGREEMENT WERE ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR PURPOSES OF SECTION 1271 ET SEQ. OF THE UNITED STATES INTERNAL REVE |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 22, 2025 |
VERADIGM INC. AMENDED AND RESTATED 2024 STOCK INCENTIVE PLAN I. INTRODUCTION Exhibit 10.1 VERADIGM INC. AMENDED AND RESTATED 2024 STOCK INCENTIVE PLAN I. INTRODUCTION 1.1. Purposes. The purposes of the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 12, 2025 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 22, 2025 |
EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is effective as of the 22nd day of April, 2025 (the “Effective Date”), by and between Tom Langan (“Executive”) and Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc., a corporation organized and existing under the laws of the State of Delaware (“Company”). Terms used in this Agreement but not |
|
| April 22, 2025 |
EX-10.2 Exhibit 10.2 April 22, 2025 Leland Westerfield Re: Renewal Agreement Dear Lee: This letter confirms our mutual agreement to extend the term of your employment as Interim Chief Financial Officer and Interim Chief Accounting Officer of Veradigm Inc. (the “Company”) under the Letter Agreement, dated December 7, 2023, between you and the Company (the “Letter Agreement”) through December 31, 20 |
|
| April 17, 2025 |
EX-16.1 EXHIBIT 16.1 GRANT THORNTON LLP April 17, 2025 4140 ParkLake Ave., Suite 130 Raleigh, NC 27612 D +1 919 881 2700 U.S. Securities and Exchange Commission F +1 919 881 2795 Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Veradigm Inc. File No. 000-32085 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Veradigm Inc. dated April 14, 2025, and agree with the sta |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (C |
|
| March 18, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 18, 2025 |
Veradigm Files Fiscal 2022 Form 10-K and Restated Financial Statements Exhibit 99.2 Veradigm Files Fiscal 2022 Form 10-K and Restated Financial Statements CHICAGO – March 18, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that it filed its comprehensive Annual Report on Form 10-K for the year ended December 31, 2022, which also contains certain restated financial statements for periods in fiscal year |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 18, 2025 |
Veradigm Provides Updates on Fiscal 2023 and 2024 and an Outlook for Fiscal 2025 Exhibit 99.1 Veradigm Provides Updates on Fiscal 2023 and 2024 and an Outlook for Fiscal 2025 CHICAGO – March 18, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, provided updates on financial information for fiscal 2023 and 2024 and an outlook for fiscal 2025. “We remain confident in Veradigm’s business model and our value proposition,” said Tom La |
|
| March 18, 2025 |
Exhibit 4.9 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Veradigm Inc. (“Veradigm,” “we,” “us” or “our”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share (“Common Stock”), and the rights (each, a “Right” |
|
| March 18, 2025 |
Veradigm Inc. Dodd-Frank Policy on Recoupment of Incentive Compensation Exhibit 97.1 VERADIGM INC. DODD-FRANK POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Board of Directors (the “Board”) of Veradigm Inc. (the “Company”) has adopted this Dodd-Frank Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-32085 VERADIGM INC. (Exact name of registrant as specified in its |
|
| March 18, 2025 |
Exhibit 10.52 allscripts healthcare solutions, inc. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made this 13th day of February, 2018 (the “Signing Date” and “Effective Date”), by and between Allscripts Healthcare Solutions, Inc., a corporation organized and existing under the laws of the State of Delaware (“Company”), and Tom Langan (“Executive”). RECITALS WHEREAS, commenc |
|
| March 18, 2025 |
Form of Restricted Stock Unit Award Agreement (Executive Chairman) (2024) Exhibit 10.43 VERADIGM INC. Restricted Stock Unit Award Agreement (Executive Chairman) THIS AGREEMENT is made as of %%OPTION DATE, ‘Month DD, YYYY”%-% (the “Grant Date”), by and between Veradigm Inc., a Delaware corporation (“Company”), and MERGEFIELD FirstName %%FIRSTNAME%-% MERGEFIELD LastName %%LASTNAME%-% ( MERGEFIELD LastName %%LASTNAME%-%). WHEREAS, MERGEFIELD LastName %%LASTNAME%-% is expec |
|
| March 18, 2025 |
8-A12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 3) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer |
|
| March 18, 2025 |
Exhibit 4.5 AMENDMENT NO. 4 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 4 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of March 18, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that certain |
|
| March 18, 2025 |
Exhibit 10.55 December 6, 2023 P. Gregory Garrison Dear Greg: It is my pleasure to offer you the position of Executive Chairman (“Executive Chairman”) of the Board of Directors (the “Board”) of Veradigm Inc. (the “Company”), pursuant to the terms of this letter agreement (the “Offer Letter”). The terms and conditions of your employment with the Company will be as follows and shall, subject to your |
|
| March 18, 2025 |
Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 18, 2025 |
EXHIBIT 21.1 VERADIGM INC. SUBSIDIARIES Subsidiary Jurisdiction or State of Organization Allscripts Holdings, LLC Delaware Allscripts Holdings 2, LLC Delaware Coniston Exchange, LLC Delaware Allscripts Healthcare US, LP Delaware Veradigm LLC North Carolina Allscripts Software, LLC Delaware California Healthcare Medical Billing, LLC California Allscripts Analytics, LLC Delaware Allscripts Next, LLC |
|
| March 18, 2025 |
Exhibit 99.1 Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to succeed Greg Garrison as Chairman CHICAGO – March 18, 2025 – Veradigm Inc. (OTCMKTS: MDRX) (“Veradigm” or the “Company”), a leading provider of healthcare data and technology solutions, announced today its Board of Dire |
|
| March 18, 2025 |
EX-10.1 Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 18, 2025, is entered into by and between Veradigm Inc., a Delaware corporation (the “Company”), and Stonehill Capital Management LLC (the “Investor”). WHEREAS: The Company’s board of directors (the “Board”) desires to appoint Jonathan Sacks, who serves as a Partner of Investo |
|
| March 18, 2025 |
Form of Restricted Stock Unit Award Agreement (Directors) (2024) Exhibit 10.42 VERADIGM INC. Restricted Stock Unit Award Agreement (Directors) THIS AGREEMENT is made as of %%OPTION DATE, ‘Month DD, YYYY”%-% (the “Grant Date”), by and between Veradigm Inc., a Delaware corporation (“Company”), and MERGEFIELD FirstName %%FIRSTNAME%-% MERGEFIELD LastName %%LASTNAME%-% ( MERGEFIELD LastName %%LASTNAME%-%). WHEREAS, MERGEFIELD LastName %%LASTNAME%-% is expected to pe |
|
| March 18, 2025 |
Exhibit 10.2 CONFIDENTIALITY AGREEMENT This confidentiality agreement (this “Confidentiality Agreement”) is made and entered into as of March 18, 2025, by and among Veradigm Inc., a Delaware corporation (the “Company”), on the one hand, and (i) Stonehill Capital Management LLC, a Delaware limited liability company (collectively with its Affiliates (as defined below), “Stonehill”) and (ii) Jonathan |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K |
|
| February 21, 2025 |
8-A12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer |
|
| February 20, 2025 |
Exhibit 99.1 Veradigm Announces Board Expansion and Changes Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors CHICAGO – February 20, 2025 – Veradigm® (OTCMKTS: MDRX) (“Veradigm” or the “Company”), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the “Agreement”) with K |
|
| February 20, 2025 |
Veradigm Amends and Extends Stockholder Rights Plan Exhibit 99.1 Veradigm Amends and Extends Stockholder Rights Plan Chicago – February 20, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the “Board”) has approved an amendment to extend the Company’s existing Stockholder Rights Plan (the “Rights Plan”). The Rights Plan, adopted on February 26, 2024, was d |
|
| February 20, 2025 |
Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 20, 2025 |
Exhibit 4.4 AMENDMENT NO. 3 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 3 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of February 20, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that cert |
|
| February 20, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 20, 2025 |
Exhibit 4.1 COOPERATION AGREEMENT This cooperation agreement (this “Agreement”) is made and entered into as of February 20, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), on the one hand, and Kent Lake PR LLC, a Puerto Rico limited liability company (“Kent Lake”), on the other hand. The Company and Kent Lake are each herein referred to as a “party” and collectively, th |
|
| February 20, 2025 |
Exhibit 4.3 AMENDMENT NO. 2 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 2 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of February 13, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that cert |
|
| January 30, 2025 |
Veradigm Announces the Resignation of Board Director Beth Altman Due to Health Reasons Exhibit 99.1 Veradigm Announces the Resignation of Board Director Beth Altman Due to Health Reasons CHICAGO – January 30, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that on January 28, 2025 Beth Altman stepped down from the Company’s Board of Directors (“Board”) due to health reasons. Her decision to resign was not the result o |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 30, 2025 |
Exhibit 99.2 Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March CHICAGO – January 30, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directo |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 31, 2024 |
Letter Agreement, dated December 31, 2024, between the Company and Leland Westerfield Exhibit 10.1 December 31, 2024 Leland Westerfield Re: Renewal Agreement Dear Lee: This letter confirms our mutual agreement to extend the term of your employment as Interim Chief Financial Officer and Interim Chief Accounting Officer of Veradigm Inc. (the “Company”) under the Letter Agreement, dated December 7, 2023, between you and the Company (the “Letter Agreement”) through June 30, 2025 (such |
|
| November 14, 2024 |
MDRX / Veradigm Inc. / Madison Avenue Partners, LP Passive Investment SC 13G/A 1 veradigm13ga1-11142024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Veradigm Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01988P108 (CUSIP Numbe |
|
| November 14, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A 2 d894473dex99a.htm EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments th |
|
| November 14, 2024 |
MDRX / Veradigm Inc. / Silver Point Capital L.P. - SC 13G Passive Investment SC 13G 1 d894473dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Veradigm Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11- |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 8, 2024 |
MDRX / Veradigm Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Veradigm Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Veradigm Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under th |
|
| October 31, 2024 |
MDRX / Veradigm Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Veradigm Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 29, 2024 |
EX-10.1 Exhibit 10.1 PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K, THIS EXHIBIT OMITS CERTAIN INFORMATION, IDENTIFIED BY [***], THAT IS NOT MATERIAL AND THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STOCKHOLDER AGREEMENT This STOCKHOLDER AGREEMENT, dated as of July 26, 2024 (this “Agreement”), is by and among Veradigm Inc. (the “Company”), Charles Myers (“Myers”) and Jessica Myers (t |
|
| June 10, 2024 |
MDRX / Veradigm Inc. / Madison Avenue Partners, LP Passive Investment SC 13G 1 veradigm13g-06042024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Veradigm Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01988P108 (CUSIP Number) Ma |
|
| May 28, 2024 |
Exhibit 99.2 Veradigm Announces Leadership Updates Tom Langan appointed as interim CEO Interim CFO Lee Westerfield extends term with Company CHICAGO – May 28, 2024 – Veradigm Inc. (OTCMKTS: MDRX, the “Company”), a leading provider of healthcare data and technology solutions, today announced that, on June 7, 2024, Tom Langan, the Company’s President and Chief Commercial Officer (CCO), will assume t |
|
| May 28, 2024 |
Form of Agreement for the Payment of Benefits Following Termination of Employment EX-10.6 Exhibit 10.6 VERADIGM INC. AGREEMENT FOR THE PAYMENT OF BENEFITS FOLLOWING TERMINATION OF EMPLOYMENT This AGREEMENT, dated as of May 21, 2024 (the “Effective Date”), between VERADIGM INC., a Delaware corporation (the “Company”), and [] (the “Executive”), W I T N E S S E T H: WHEREAS, the Executive is employed by the Company in the position of [] of the Company; and WHEREAS, the Company and |
|
| May 28, 2024 |
Letter Agreement, dated May 27, 2024, between the Company and Leland Westerfield EX-10.1 Exhibit 10.1 CONFIDENTIAL DRAFT May 27, 2024 Leland Westerfield Re: Renewal Agreement Dear Lee: This letter confirms our mutual agreement to extend the term of your employment as Interim Chief Financial Officer and Interim Chief Accounting Officer of Veradigm Inc. (the “Company”) under the Letter Agreement, dated December 7, 2023, between you and the Company (the “Letter Agreement”) throug |
|
| May 28, 2024 |
Form of Performance Unit Award Agreement EX-10.4 Exhibit 10.4 Name: [] Number of Shares Subject to the Stock [] Date of Grant: [] VERADIGM INC. Restricted Stock Unit Award Agreement Performance-Based Vesting – Relative TSR THIS AGREEMENT is made as of the Grant Date, by and between Veradigm Inc., a Delaware corporation (“Company”), and [] (the participant). WHEREAS, in recognition of your services to the Company, the Company considers it |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 28, 2024 |
Veradigm Inc. 2024 Stock Incentive Plan EX-10.5 Exhibit 10.5 VERADIGM INC. 2024 STOCK INCENTIVE PLAN I. INTRODUCTION 1.1. Purposes. The purposes of the Veradigm Inc. 2024 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, (ii) to advance the interests of |
|
| May 28, 2024 |
Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance EX-99.1 Exhibit 99.1 Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance CHICAGO – May 28, 2024 – Veradigm Inc. (OTCMKTS: MDRX, the “Company”), a leading provider of healthcare data and technology solutions, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of the evaluation process, Veradigm will explore pot |
|
| May 28, 2024 |
Form of Restricted Stock Unit Award Agreement Exhibit 10.2 Name: [] Number of Shares Subject to the Stock [] Date of Grant: [] VERADIGM INC. Restricted Stock Unit Award Agreement THIS AGREEMENT is made as of the Grant Date, by and between Veradigm Inc., a Delaware corporation (“Company”), and [] (the participant). WHEREAS, in recognition of your services to the Company, the Company considers it desirable and in its best interests that the par |
|
| May 28, 2024 |
Form of Restricted Stock Unit Award Agreement (Westerfield) Exhibit 10.3 Name: Leland Westerfield Number of Shares Subject to the Stock [ ] Date of Grant: [ ] VERADIGM INC. Restricted Stock Unit Award Agreement THIS AGREEMENT is made as of the Grant Date, by and between Veradigm Inc., a Delaware corporation (“Company”), and the participant (the participant). WHEREAS, in recognition of your services to the Company, the Company considers it desirable |
|
| May 16, 2024 |
MDRX / Veradigm Inc. / Kent Lake Capital LLC - SC 13D Activist Investment SC 13D 1 n4288x1-sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Veradigm Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01988P108 (CUSIP N |
|
| May 16, 2024 |
Joint Filing Agreement, dated May 16, 2024. EX-99.1 2 exh99-1.htm JOINT FILING AGREEMENT, DATED MAY 16, 2024 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, par value $0.01 per |
|
| May 13, 2024 |
Exhibit 4.2 AMENDMENT NO. 1 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 1 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of May 10, 2024, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that certain S |
|
| May 13, 2024 |
8-A12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ |
|
| May 13, 2024 |
Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 1, 2024 |
Exhibit 10.1 EXECUTION VERSION THIRD AMENDMENT THIRD AMENDMENT, dated as of March 29, 2024 (this “Amendment”), to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022 (as amended by the First Amendment, dated as of November 20, 2023, as amended by the Second Amendment, dated as of January 31, 2024, and as further amended, supplemented or otherwise modified from time to time |
|
| March 13, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 13, 2024 |
Veradigm Announces Initial Financial Guidance for Fiscal 2024 Exhibit 99.1 Veradigm Announces Initial Financial Guidance for Fiscal 2024 CHICAGO – March 13, 2024 – Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Co |
|
| March 13, 2024 |
Barclays Healthcare Investor Conference Veradigm Miami, Florida | March 13, 2024 Exhibit 99. |
|
| March 12, 2024 |
MDRX / Veradigm Inc. / Kent Lake Capital LLC - VERADIGM 13G Passive Investment SC 13G 1 mdrx13gv1.htm VERADIGM 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Veradigm Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01988P108 (CUSIP Number) March 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| March 11, 2024 |
MDRX / Veradigm Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Veradigm Inc Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: February 29, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| March 8, 2024 |
MDRX / Veradigm Inc. / Newtyn Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VERADIGM INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 01988P108 (CUSIP Number) February 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| March 4, 2024 |
MDRX / Veradigm Inc. / STONEHILL CAPITAL MANAGEMENT LLC - SC 13G Passive Investment SC 13G 1 d759701dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Veradigm Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01988P108 (CUSIP Number) February 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| March 4, 2024 |
EX-99.1 2 d759701dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT OF JOINTING FILING Stonehill Capital Management LLC, Stonehill Master Fund Ltd., Stonehill Institutional Partners, L.P, John Motulsky, Peter Sisitsky, Michael Thoyer, Jonathan Sacks, Michael Stern and Samir Arora hereby agree that the Statement on Schedule 13G to which this agreement is attached as an exhibit as well as all future amendments |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 28, 2024 |
Exhibit 99.1 Veradigm Receives Expected Delisting Notice from Nasdaq Continues to Work Diligently Towards Regaining Compliance CHICAGO – February 28, 2024 – Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, announced today that, as expected, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 27, 2024 |
Exhibit 99.2 Veradigm Provides Update on its Financial Restatement Process Expects Not to File Required Financial Statements by Nasdaq’s February 27, 2024 Deadline Working Diligently to File Required Financial Statements and Restore Listing Adopts Limited Duration Stockholder Rights Plan CHICAGO – February 27, 2024 – Veradigm Inc. (NASDAQ: MDRX) (the “Company”), a leading provider of healthcare da |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 222 Merch |
|
| February 27, 2024 |
Exhibit 4.1 STOCKHOLDER RIGHTS AGREEMENT Veradigm Inc. and Broadridge Corporate Issuer Solutions, LLC, as Rights Agent Dated as of February 26, 2024 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 9 Section 3. Issuance of Rights Certificates 10 Section 4. Form of Rights Certificates 12 Section 5. Countersignature and Registration 13 Section 6. Transfe |
|
| February 27, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF VERADIGM INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that the following resolution was duly adopted by the board of directors of Veradigm Inc., a Delaware corporation (the “Corporation”), on February 26, 2024: RESOLVED, that pursuant t |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 27, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF VERADIGM INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that the following resolution was duly adopted by the board of directors of Veradigm Inc., a Delaware corporation (the “Corporation”), on February 26, 2024: RESOLVED, that pursuant t |
|
| February 27, 2024 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among VERADIGM INC., VERADIGM MERGER SUB, INC., CASCADE BIO, INC., EACH OF THE DESIGNATED EQUITYHOLDERS, EACH OF THE OTHER MANAGEMENT EQUITYHOLDERS, and FORTIS ADVISORS LLC, as Equityholder Representative FEBRUARY 21, 2024 TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INTERPRETATIONS 2 1.1 Definitions 2 1.2 Additional Defined Terms 22 1.3 Interp |
|
| February 27, 2024 |
Exhibit 4.1 STOCKHOLDER RIGHTS AGREEMENT Veradigm Inc. and Broadridge Corporate Issuer Solutions, LLC, as Rights Agent Dated as of February 26, 2024 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 9 Section 3. Issuance of Rights Certificates 10 Section 4. Form of Rights Certificates 12 Section 5. Countersignature and Registration 13 Section 6. Transfe |
|
| February 27, 2024 |
Exhibit 99.1 Veradigm to Acquire ScienceIO Veradigm to Leverage ScienceIO’s Leading Healthcare Artificial Intelligence (AI) Platform on the Company’s Large-Scale, High-Quality Data Set to Build Advanced, Private Language Models for Healthcare Expected to Provide Highly Differentiated and More Advanced Products to Veradigm Customers Acquisition Will Help Accelerate Platform Improvements Across the |
|
| February 13, 2024 |
MDRX / Veradigm Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02199-veradigminc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Veradigm Inc Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 9, 2024 |
MDRX / Veradigm Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Veradigm Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 8, 2024 |
MDRX / Veradigm Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Veradigm Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 5, 2024 |
Exhibit 4.1 Execution Copy VERADIGM INC. (formerly known as Allscripts Healthcare Solutions, Inc.) AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 5, 2024 TO THE INDENTURE Dated as of December 9, 2019 0.875% Convertible Senior Notes due 2027 FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of February 5, 2024, be |
|
| February 5, 2024 |
Exhibit 10.2 Execution Version Wells Fargo Bank, National Association 30 Hudson Yards New York, NY 10001-2170 DATE: February 5, 2024 TO: Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.) 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 ATTENTION: General Counsel TELEPHONE: (312) 386-6751 EMAIL: [email protected] FROM: Wells Fargo Bank, National Association SUBJECT: Amend |
|
| February 5, 2024 |
Exhibit 10.4 Execution Version Deutsche Bank Deutsche Bank AG, London Branch Winchester house 1 Great Winchester St, London EC2N 2DB Telephone: 44 20 7545 8000 c/o Deutsche Bank Securities Inc. 60 Wall Street New York, NY 10005 Telephone: (212) 250-2500 DATE: February 5, 2024 TO: Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.) 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 AT |
|
| February 5, 2024 |
Exhibit 10.3 Execution Version Bank of America, N.A. One Bryant Park New York, NY 10036 DATE: February 5, 2024 TO: Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.) 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 ATTENTION: General Counsel TELEPHONE: (312) 386-6751 EMAIL: [email protected] FROM: Bank of America, N.A. SUBJECT: Amendment No. 1 To Capped Call Transactions |
|
| February 5, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 5, 2024 |
Exhibit 10.1 Execution Version JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 DATE: February 5, 2024 TO: Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.) 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 ATTENTION: General Counsel TELEPHONE: (312) 386-6751 EMAIL: [email protected] FROM: JPMorgan Chase Bank, National Associ |
|
| January 31, 2024 |
Exhibit 10.1 EXECUTION VERSION SECOND AMENDMENT SECOND AMENDMENT, dated as of January 31, 2024 (this “Amendment”), to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022 (as amended by the First Amendment, dated as of November 20, 2023, and as further amended, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), among VERAD |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 10, 2024 |
Exh. 99.1 New Veradigm Leadership Provides Outlook on Business and Strategy, and Refreshed Financial Estimates for Fiscal 2023 CHICAGO – January 10, 2024 – The new leadership team at Veradigm Inc. (NASDAQ: MDRX),a leading provider of healthcare data and technology solutions, has provided refreshed estimated, unaudited ranges of financial information for fiscal 2023. Dr. Shih-Yin Ho, Interim CEO, a |
|
| January 10, 2024 |
JP Morgan Healthcare Conference Building for the Future January 10, 2024 Exh. 99.2 JP Morgan Healthcare Conference Building for the Future January 10, 2024 Exh. 99.2 Disclaimer & Forward-Looking Statements The estimated financial results contained in this presentation are preliminary, and final results for fiscal year 2023 may change. These preliminary results are based upon our estimates and are subject to completion of our financial closing procedures. In addition, these preli |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 13, 2023 |
Exhibit 99.1 Veradigm Inc. Announces that Nasdaq Hearings Panel has Granted its Continued Listing, Pending Return to Compliance with Nasdaq Filing Requirements CHICAGO – December 13, 2023 – Veradigm Inc. (NASDAQ: MDRX (the “Company”)) announced today that it received a decision from the Nasdaq Hearings Panel (the “Panel”) granting its request for continued listing on the Nasdaq Capital Market, sub |
|
| December 8, 2023 |
Offer Letter Agreement, effective as of December 7, 2023, between Veradigm Inc. and Shih-Yin Ho Exhibit 10.1 December 6, 2023 Dr. Shih-Yin Ho Dear Yin: It is my pleasure to offer you the position of Interim Chief Executive Officer (“Interim CEO”) of Veradigm Inc. (the “Company”), pursuant to the terms of this letter agreement (the “Offer Letter”). The terms and conditions of your employment with the Company will be as follows and shall, subject to your satisfaction of the “Conditions to Empl |
|
| December 8, 2023 |
Consulting Agreement, effective as of December 7, 2023, between Veradigm Inc. and Leah S. Jones EX-10.6 Exhibit 10.6 CONSULTING AGREEMENT Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc.) (“Company”) and Leah Jones (“Contractor”) hereby enter into this Consulting Agreement (“Agreement”) effective as of the 7th day of December, 2023 (“Effective Date”) for good and valuable consideration and mutually agree as follows: 1. Consulting Period. Subject to the terms of this Agr |
|
| December 8, 2023 |
EX-99.1 Exhibit 99.1 Veradigm Inc. Announces Leadership Transition Greg Garrison Named Executive Chairman; Dr. Shih-Yin Ho Appointed Interim CEO; Lee Westerfield Appointed Interim CFO CHICAGO – DECEMBER 8, 2023 – Veradigm Inc. (Nasdaq: MDRX) announced today that the Company’s Board of Directors appointed current Chairman, Greg Garrison, as Executive Chairman, and current director, Dr. Shih-Yin (“Y |
|
| December 8, 2023 |
Second Amendment to By-Laws of Veradigm Inc. EX-3.1 Exhibit 3.1 SECOND AMENDMENT TO BY-LAWS OF VERADIGM INC. (A DELAWARE CORPORATION), AS AMENDED AND RESTATED ON AUGUST 18, 2015 This Second Amendment (this “Amendment”) to the By-Laws, as amended and restated on August 18, 2015 and as further amended on January 1, 2023 (the “By-Laws”), of Veradigm Inc., a Delaware corporation f/k/a Allscripts Healthcare Solutions, Inc. (the “Corporation”), is |
|
| December 8, 2023 |
EX-10.3 Exhibit 10.3 CONSULTING AGREEMENT Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc.) (“Company”) and Leland Westerfield, sole and managing member of Wilcox Capital LLC (“Contractor”) hereby enter into this Consulting Agreement (“Agreement”) effective as of December 7, 2023 (“Effective Date”) for good and valuable consideration and mutually agree as follows: 1. Consulti |
|
| December 8, 2023 |
Separation Agreement, dated as of December 6, 2023, between Veradigm Inc. and Leah S. Jones Exhibit 10.5 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is effective as of the 6th day of December, 2023 (the “Effective Date”), by and between Leah Jones (“Executive”) and Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc. (“Allscripts”)), a corporation organized and existing under the laws of the State of Delaware (“Company”). WHEREAS, Company and Execu |
|
| December 8, 2023 |
Separation Agreement, dated as of December 6, 2023, between Veradigm Inc. and Richard J. Poulton Exhibit 10.4 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is effective as of the 6th day of December, 2023 (the “Effective Date”), by and between Richard Poulton (“Executive”) and Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc. (“Allscripts”)), a corporation organized and existing under the laws of the State of Delaware (“Company”). Terms used in this Ag |
|
| December 8, 2023 |
EX-10.2 Exhibit 10.2 December 7, 2023 Leland Westerfield [*****] Dear Lee: It is my pleasure to offer you the position of Interim Chief Financial Officer (“Interim CFO”) of Veradigm Inc. (the “Company”), pursuant to the terms of this letter agreement (the “Offer Letter”). The terms and conditions of your employment with the Company will be as follows and shall, subject to your satisfaction of the |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 24, 2023 |
Exhibit 10.1 Exhibit A EXECUTION VERSION FIRST AMENDMENT FIRST AMENDMENT, dated as of November 20, 2023 (this “Amendment”), to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022 (as amended, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), among VERADIGM INC. (under its former name ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 17, 2023 |
Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing Exhibit 99.1 Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing CHICAGO – November 17, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 ( |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr |
|
| October 10, 2023 |
Veradigm Inc. Announces Receipt of Nasdaq Stay Extension Exh. 99.1 Veradigm Inc. Announces Receipt of Nasdaq Stay Extension CHICAGO – October 9, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that, on October 6, 2023, it received a notice from Nasdaq indicating that the temporary stay of delisting of the Company’s common stock has been extended pending a hearing before the Nasdaq Hearings Panel (the “Panel”) on November 16, 2023, and the issuance o |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 06, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 22, 2023 |
Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal Exh. 99.1 Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal CHICAGO – September 22, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that, on September 20, 2023 and as anticipated in its September 18 release, it received a notice from Nasdaq indicating that the Company’s shares would be delisted due to noncompliance with Nasdaq Listing Rule 5250(c)(1), because the |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 18, 2023 |
Veradigm Inc. Provides Audit Update and Updates Financial Guidance for 2023 Exh. 99.1 Veradigm Inc. Provides Audit Update and Updates Financial Guidance for 2023 CHICAGO – September 18, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that the work effort to conclude on its previously disclosed accounting and internal control errors has taken longer than previously expected, and more time is needed to complete its audit procedures. As such, today the Company will not b |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 18, 2023 |
Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing Exh. 99.1 Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing CHICAGO – August 18, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the “ |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit |
|
| June 14, 2023 |
Veradigm Inc. Receives Approval from Nasdaq of Plan to Regain Listing Compliance Exh. 99.1 Veradigm Inc. Receives Approval from Nasdaq of Plan to Regain Listing Compliance CHICAGO – JUNE 13, 2023 –Veradigm Inc. (Nasdaq: MDRX) announced today that Nasdaq has accepted the Company’s plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) and granted the Company an exception until September 18, 2023 to file its Annual Report on Form 10-K for the year ended December 31, 2022 |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 19, 2023 |
Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing Exh. 99.1 Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing CHICAGO – MAY 19, 2023 –Veradigm Inc. (Nasdaq: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| March 22, 2023 |
Exh. 99.1 Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results CHICAGO – MARCH 22, 2023 –Veradigm Inc. (Nasdaq: MDRX) announced today an update on the status of its year-end audit procedures for 2022. As the Company disclosed on February 28, 2023, due to an expansion of year-end audit procedures, the |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 28, 2023 |
Veradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results EX-99.1 Exhibit 99.1 Veradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results CHICAGO – FEBRUARY 28, 2023 – Veradigm Inc. (NASDAQ: MDRX), announced today that in conjunction with its year-end audit procedures it has detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to repo |
|
| February 28, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 28, 2023 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11 |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 22, 2023 |
Exh. 99.1 Veradigm Announces Two New Appointments to its Board Pharmaceutical executive Susan Rodriguez and digital health/pharma services entrepreneur Dr. Shih-Yin Ho join Board of Directors CHICAGO – FEBRUARY 22, 2023 – Susan Rodriguez and Shih-Yin Ho, MD have been named to the Board of Directors of Veradigm Inc. (NASDAQ: MDRX). With their combined experience in the pharmaceutical industry, digi |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Allscripts Healthcare Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2023 |
MDRX / Allscripts Healthcare Solutions Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Allscripts Healthcare Solutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 11, 2023 |
Veradigm J.P. Morgan Healthcare Conference January 11, 2023 Exh. 99.2 Veradigm J.P. Morgan Healthcare Conference January 11, 2023 Exh. 99.2 Veradigm | Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our 2023 outlook. These forward-looking statements are based on the current beliefs and expectations of Veradigm management, only |
|
| January 11, 2023 |
Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023 Exh. 99.1 Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023 CHICAGO – JANUARY 11, 2023 – Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase p |
|
| January 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 01, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 4, 2023 |
Exh. 3.1 CERTIFICATE OF AMENDMENT OF FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: FIRST: That the Board of Directors of the Corporation, at a meeting duly held, adopted a resolution proposing and |
|
| January 4, 2023 |
Allscripts Announces Corporate Name Change to Veradigm Inc. Exh. 99.1 Allscripts Announces Corporate Name Change to Veradigm Inc. CHICAGO ? JANUARY 3, 2023 ? Allscripts Healthcare Solutions, Inc. announced today that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand during 2022, and Allscripts will now formally be known as Veradigm. The US healthcare ec |
|
| January 4, 2023 |
First Amendment to By-Laws of Allscripts Healthcare Solutions, Inc. Exh. 3.2 FIRST AMENDMENT TO BY-LAWS OF ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (a Delaware corporation), as amended and restated on August 18, 2015 This First Amendment (this ?Amendment?) to the By-Laws, as amended and restated on August 18, 2015 (the ?By-Laws?), of Allscripts Healthcare Solutions, Inc., a Delaware corporation (the ?Corporation?), is made as of January 1, 2023 in accordance with Art |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name o |
|
| November 7, 2022 |
Form of Restricted Stock Unit Award Agreement for CEO Awards Program ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Restricted Stock Unit Award Agreement CEO Awards Program ? One Year Vesting THIS AGREEMENT is made as of ?Date? (the ?Grant Date?), by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (?Company?), and ?FirstName? ?LastName? (?LastName?). WHEREAS, ?LastName? is expected to perform valuable services for the Company and the Company consid |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 3, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporati |
|
| November 3, 2022 |
Allscripts announces third quarter of 2022 results Exhibit 99.1 Allscripts announces third quarter of 2022 results Third quarter consolidated revenue of $152 million Third quarter consolidated operating profit up over 30% year-over-year Generated $42 million of cash flow from continuing operations in the quarter CHICAGO-(BUSINESS WIRE)-November 3, 2022-Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial result |
|
| September 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorpora |
|
| September 28, 2022 |
Investor Day September 28, 2022 Allscripts/Veradigm Exhibit 99.1 Allscripts| Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subj |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Reg |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 4, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation |
|
| August 4, 2022 |
Allscripts Announces Second Quarter of 2022 Results Exhibit 99.1 Allscripts Announces Second Quarter of 2022 Results Second quarter bookings of $107 million and $172 million year-to-date, up 10% from the first half of 2021 Generated $42 million of cash flow from continuing operations in the quarter CHICAGO-(BUSINESS WIRE)-August 4, 2022-Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three a |
|
| June 22, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Re |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 6, 2022 |
DEF 14A 1 mdrx-def14a20220621.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| May 5, 2022 |
Allscripts announces first quarter of 2022 results Exhibit 99.1 Allscripts announces first quarter of 2022 results • First quarter GAAP diluted EPS of $0.17; non-GAAP diluted EPS of $0.13 • Closed the sale of Hospital & Large Physician Practices business segment to Constellation Software • Generated $35 million of cash flow from continuing operations in the quarter CHICAGO – May 5, 2022 – Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allsc |
|
| May 5, 2022 |
Exhibit 10.1 SECOND AMENDMENT (“AMENDMENT”) TO THE EMPLOYMENT AGREEMENT BETWEEN ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. AND PAUL M. BLACK WHEREAS, Allscripts Healthcare Solutions, Inc. (the “Company”) and Paul M. Black (“Executive”) previously entered into an Employment Agreement dated December 19, 2012, and an Amendment No. 1 to Employment Agreement dated October 1, 2015 (collectively, the “Agreeme |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) |
|
| May 5, 2022 |
Exhibit 99.2 Allscripts Healthcare Solutions, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) Overview On May 2, 2022, Allscripts Healthcare Solutions, Inc., a Delaware corporation (the “Company”), Allscripts Healthcare, LLC, a North Carolina limited liability company (“Allscripts Healthcare”), Allscripts Software, LLC, a Delaware limited |
|
| May 2, 2022 |
Exhibit 10.1 Execution Version THIRD AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 29, 2022 among ALLSCRIPTS HEALTHCARE SOLUTIONS, INC., as Borrower, ALLSCRIPTS HEALTHCARE, LLC as Co-Borrower, The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent U.S. BANK NATIONAL ASSOCIATION, BANK OF AMERICA, N.A., BMO HARRIS BANK N.A., ROYAL BANK OF CANADA and PNC BANK, NATIONAL A |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation |
|
| May 2, 2022 |
Allscripts Closes Sale of Hospital and Large Physician Practices Business to Constellation Software Exhibit 99.1 Allscripts Closes Sale of Hospital and Large Physician Practices Business to Constellation Software CHICAGO ? May 2, 2022 ? Allscripts Healthcare Solutions, Inc. (Nasdaq:MDRX) today announced that it has completed the sale of the net assets of the Allscripts Hospital and Large Physician Practices business segment to Constellation Software Inc. (TSX:CSU), through its wholly-owned subsi |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of regis |
|
| March 4, 2022 |
EXHIBIT 2.1 Execution Version Purchase Agreement by and among Allscripts Healthcare Solutions, Inc., Allscripts Healthcare, LLC, Allscripts Software, LLC, PF2 EIS LLC, Allscripts IHC, LLC, Allscripts Healthcare US, LP, HARRIS DAWN HOLDINGS INC. and CONSTELLATION SOFTWARE INC. Dated as of March 2, 2022 Table of Contents Article I DEFINITIONS 2 Article II The transaction 2 2.1 Purchase and Sale 2 2. |
|
| March 4, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) |
|
| March 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) |
|
| March 3, 2022 |
Allscripts Healthcare Solutions Investor Update, March 3, 2022 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including the preliminary financial information included in this presentation, are based on the current beliefs and expectations of Allscripts manage |
|
| March 3, 2022 |
Exhibit 99.1 Allscripts to Sell the Net Assets of Its Hospitals & Large Physician Practices Business Segment to Constellation Software CHICAGO ? March 2, 2022 ? Allscripts Healthcare Solutions (NASDAQ: MDRX) (?Allscripts?) announced today that it has reached an agreement with Constellation Software Inc. (TSX:CSU), through its wholly-owned subsidiary N. Harris Computer Corporation (?Harris?), to se |
|
| March 3, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) |
|
| February 25, 2022 |
Form of Performance-Based Restricted Stock Unit Award Agreement Exhibit 10.29 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Performance-Based Restricted Stock Unit Award Agreement Performance-Based Vesting THIS AGREEMENT is made as of [], [] (the ?Grant Date?), by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (?Company?), and ?FirstName? ?LastName? (the ?Participant?). WHEREAS, the Participant is expected to perform valuable services for th |
|
| February 25, 2022 |
Form of Performance-Based Restricted Stock Unit Award Agreement (TSR) (Relative) (2021) Exhibit 10.28 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Performance-Based Restricted Stock Unit Award Agreement Performance-Based Vesting ? Relative TSR THIS AGREEMENT is made as of [] (the ?Grant Date?), by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (?Company?), and ?FirstName? ?LastName? (the ?Participant?). WHEREAS, the Participant is expected to perform valuable serv |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of registr |
|
| February 25, 2022 |
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. EXHIBIT 21.1 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. SUBSIDIARIES Subsidiary Jurisdiction or State of Organization Allscripts Holdings, LLC Delaware Allscripts Holdings 2, LLC Delaware Coniston Exchange, LLC Delaware Allscripts Healthcare US, LP Delaware Allscripts Healthcare, LLC North Carolina Allscripts Managed Services, LLC Delaware Allscripts Software, LLC Delaware California Healthcare Medical |
|
| February 25, 2022 |
Form of Restricted Stock Unit Award Agreement (Directors) (2019) Exhibit 10.20 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Restricted Stock Unit Award Agreement (Directors) THIS AGREEMENT is made as of (the ?Grant Date?), by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (?Company?), and {First Name} {Last Name} (?{Last Name}?). WHEREAS, {Last Name} is expected to perform valuable services for the Company as a member of the Board of Directo |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporat |
|
| February 24, 2022 |
Allscripts Announces Fourth Quarter and Fiscal Year 2021 Results Exhibit 99.1 Allscripts Announces Fourth Quarter and Fiscal Year 2021 Results Fourth quarter GAAP diluted EPS of $0.68; non-GAAP diluted EPS of $0.79 Fourth quarter bookings of $219 million up 21% from the fourth quarter of 2020 Generated $66 million of cash flow from continuing operations in the quarter CHICAGO-(BUSINESS WIRE)-February 24, 2022-Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) |
|
| February 10, 2022 |
MDRX / Allscripts Healthcare Solutions Inc / SHAPIRO CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2022 |
MDRX / Allscripts Healthcare Solutions Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Allscripts Healthcare Solutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Allscripts Healthcare Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporati |
|
| January 24, 2022 |
Twelve Months Ended December 31, Exh. 99.1 Allscripts Announces Preliminary Fourth Quarter and Fiscal Year 2021 Results and New Share Repurchase Program CHICAGO ? January 24, 2022 ? Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) today announced preliminary financial results for the three and twelve months ended December 31, 2021. Revenue for the fourth quarter of 2021 is expected to be between $390 million and |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name o |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 4, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporati |
|
| November 4, 2021 |
Allscripts Announces Third Quarter 2021 Results Exhibit 99.1 Allscripts Announces Third Quarter 2021 Results Third quarter GAAP diluted EPS of $0.12; non-GAAP diluted EPS of $0.27, up 145% year-over-year Generated $57 million of cash flow from continuing operations and $35 million of free cash flow in the third quarter Increasing 2021 outlook for Adjusted EBITDA and free cash flow CHICAGO-(BUSINESS WIRE)-November 4, 2021-Allscripts Healthcare S |
|
| August 6, 2021 |
Exhibit 10.1 FIRST AMENDMENT (?AMENDMENT?) TO THE EMPLOYMENT AGREEMENT BETWEEN ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. AND LISA KHOREY WHEREAS, Allscripts Healthcare Solutions, Inc. (the ?Company?) and Lisa Khorey (?Executive?) previously entered into an Employment Agreement dated November 1, 2016 (the ?Agreement?); and WHEREAS, the Company and Executive previously entered into the Agreement and now |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Reg |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 5, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation |
|
| August 5, 2021 |
Allscripts Announces Second Quarter 2021 Results Exhibit 99.1 Allscripts Announces Second Quarter 2021 Results Second quarter GAAP diluted EPS of $0.15; non-GAAP diluted EPS of $0.23, up 35% year-over-year Generated $69 million of cash flow from continuing operations and $51 million of free cash flow in the second quarter Increasing 2021 outlook for Adjusted EBITDA and free cash flow CHICAGO-(BUSINESS WIRE)-August 5, 2021-Allscripts Healthcare S |
|
| June 15, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) |
|
| May 26, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Re |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 29, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation |
|
| April 29, 2021 |
Allscripts Announces First Quarter 2021 Results EX-99.1 2 a52420285ex991.htm EXHIBIT 99.1 Exhibit 99.1 Allscripts Announces First Quarter 2021 Results First quarter GAAP EPS of $0.06; non-GAAP diluted EPS of $0.19 First quarter bookings of $194 million up 6% from the first quarter of 2020 Generated $56 million of cash flow from continuing operations and $35 million of free cash flow in the first quarter CHICAGO-(BUSINESS WIRE)-April 29, 2021-Al |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* Allscripts Healthcare Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) March 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 26, 2021 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Allscripts Healthcare Solutions, Inc. (?Allscripts,? ?we,? ?us? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock. The following summary of the material terms of our capital stock is not meant to be |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of registr |
|
| February 26, 2021 |
Accelerated Share Repurchase Master Confirmation dated November 30, 2020 Exhibit 10.6 EXECUTED VERSION November 30, 2020 From: JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY, 10179 To: Allscripts Healthcare Solutions, Inc. 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 Attention: Richard J. Poulton Telephone No.:312.506.1216 Email:[email protected]; [email protected] Re: Master Confirmation?Uncol |
|
| February 26, 2021 |
Accelerated Share Repurchase Master Confirmation dated November 30, 2020 Exhibit 10.5 EXECUTED VERSION November 30, 2020 From: Wells Fargo Bank, National Association 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] To: Allscripts Healthcare Solutions, Inc. 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 Attention: Richard J. Poulton Telephone No.:312.506.1216 Email:[email protected]; legal.notices@allscri |
|
| February 26, 2021 |
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. EXHIBIT 21.1 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. SUBSIDIARIES Subsidiary Jurisdiction or State of Organization Allscripts Holdings, LLC Delaware Allscripts Holdings 2, LLC Delaware Coniston Exchange, LLC Delaware Allscripts Healthcare US, LP Delaware Allscripts Healthcare, LLC North Carolina Allscripts Managed Services, LLC Delaware Allscripts Software, LLC Delaware California Healthcare Medical |
|
| February 25, 2021 |
Allscripts Announces Fourth Quarter 2020 Results and Outlook For 2021 Exhibit 99.1 Allscripts Announces Fourth Quarter 2020 Results and Outlook For 2021 Fourth quarter GAAP EPS of $4.82; 71% year-over-year growth in non-GAAP diluted EPS to $0.29 Closed sales of EPSi and CarePort Health and recognized a combined pre-tax gain of $1.2 billion Repurchased $280 million of stock in the quarter and ended the quarter in a net cash position CHICAGO-(BUSINESS WIRE)-February 2 |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 25, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Allscripts Healthcare Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Allscripts Healthcare Solutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* Allscripts Healthcare Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| January 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporati |
|
| January 12, 2021 |
Allscripts Healthcare Solutions J.P. Morgan Virtual Healthcare Conference| January 2021 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including the preliminary financial information included in this presentation, are based on the current beliefs and expectat |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2020 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporat |
|
| January 4, 2021 |
Allscripts closes previously announced sale of CarePort Health business Exhibit 99.1 Allscripts closes previously announced sale of CarePort Health business CHICAGO – January 4, 2021 – On December 31, 2020, Allscripts (NASDAQ: MDRX) closed the previously announced sale of its CarePort Health business to WellSky® Corporation for $1.35 billion. CarePort solutions assist hundreds of hospitals and thousands of post-acute care providers to efficiently coordinate and transi |
|
| January 4, 2021 |
Exhibit 99.2 Allscripts Healthcare Solutions, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) Overview On December 31, 2020, Allscripts Healthcare, LLC, a North Carolina limited liability company (“Allscripts Healthcare”) and subsidiary of Allscripts Healthcare Solutions, Inc., a Delaware corporation (the “Company”), completed the previous |
|
| December 1, 2020 |
Allscripts Announces $200 Million Accelerated Share Repurchase Exhibit 99.1 Allscripts Announces $200 Million Accelerated Share Repurchase CHICAGO – December 1, 2020 – Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced that as part of its capital return program it has entered into accelerated share repurchase (“ASR”) transactions with each of JPMorgan Chase Bank, National Association and Wells Fargo Bank, National Association to repurchase an aggr |
|
| December 1, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2020 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporat |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name o |
|
| October 30, 2020 |
Exhibit 99.1 Allscripts Healthcare Solutions, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) Overview On October 15, 2020, Allscripts Healthcare Solutions, Inc. (the “Company”), Allscripts Healthcare, LLC and Allscripts Software, LLC, (collectively, the “EPSi Sellers”) completed the previously-announced divestiture of the EPSi Sellers’ bu |
|
| October 30, 2020 |
Financial Statements and Exhibits - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2020 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdi |
|
| October 29, 2020 |
Allscripts Announces Third Quarter 2020 Results Exhibit 99.1 Allscripts Announces Third Quarter 2020 Results Third quarter operating margin and Adjusted EBITDA margin increased both year-over-year and sequentially GAAP EPS of $0.00; 18% year-over-year growth in non-GAAP diluted EPS to $0.20 Generated $53 million of operating cash flow and $27 million of free cash flow in the third quarter CHICAGO-(BUSINESS WIRE)-October 29, 2020-Allscripts Heal |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2020 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. |
